Clinical trials: Neoplasms, Oral
Genital Neoplasms, Female
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
- Trial name
- NCT02182245
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
Safety Study of SLC-391 in Subjects With Solid Tumors
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties.
- Trial name
- NCT03990454
- Testing
- SLC-391
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- SignalChem Lifesciences Corporation
NSCLC Stage IV, NSCLC, Stage III
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Primary Objectives: To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT03130829
- Testing
- Oligo Fucoidan
- Where
- 3 sites in Taiwan
- Sponsor
- Hi-Q Marine Biotech International, Ltd.
Neoplasms
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid…
- Trial name
- NCT01022853
- Testing
- BI 6727, BIBF 1120
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
The primary objective of this trial is to determine the safety and tolerability of BI 853520 monotherapy by defining the maximum tolerated dose (MTD) and recommending the dose for further trials in the development of this…
- Trial name
- NCT01335269
- Testing
- BI 853520
- Where
- 5 sites in Canada, Netherlands
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Follicular Lymphoma
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off"…
- Trial name
- FORERUNNER (NCT03600441)
- Testing
- Abexinostat
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 139 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Solid Tumors
Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer
The purpose of this study is to determine the safety and toxicity profile of TAK-593 and determine the maximum tolerated dose of TAK-593.
- Trial name
- NCT00773929
- Testing
- TAK-593
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Head and Neck Cancer
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022217
- Testing
- carboplatin, cisplatin-e therapeutic implant, paclitaxel
- Where
- 4 sites in United States
- Sponsor
- Matrix Pharmaceutical
Prostate Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (<50 ng/dL).
- Trial name
- NCT02083185
- Testing
- Relugolix, Leuprorelin
- Where
- 23 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
The LUME-Lung3 study is in 2 parts: Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.
- Trial name
- NCT01346540
- Testing
- BIBF 1120
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed…
- Trial name
- NCT02295774
- Testing
- Methylene Blue MMX tablets
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Neoplasms, Breast
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients.
- Trial name
- NCT00258050
- Testing
- Midazolam, Lapatinib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.
- Trial name
- NCT00750425
- Testing
- cediranib (RECENTIN TM, AZD2171)
- Where
- 5 sites in Canada, Denmark
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Endometrial Cancer
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.
- Trial name
- NCT00910091
- Testing
- BN83495, Megestrol Acetate (MA)
- Where
- 54 sites in Belgium, Czechia and 10 more
- Volunteers
- 73 people
- Sponsor
- Ipsen
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Advanced Cancer, Refractory Cancer
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are…
- Conditions
- Advanced Cancer, Refractory Cancer, Tumor Gastric
- Trial name
- NCT04861987
- Testing
- PCS6422 and capecitabine
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Processa Pharmaceuticals
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
- Conditions
- Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT04849416
- Testing
- LOXO-305
- Where
- 22 sites in China
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
The overall objective of this Phase 1 study is to evaluate the safety, Pharmacokinetics (PK), and anti-tumor activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with Kirsten Rat Sarcoma (KRAS)…
- Trial name
- NCT05768321
- Testing
- GEC255 tablets
- Where
- China
- Volunteers
- 70 people
- Sponsor
- GenEros Biopharma Hangzhou Ltd
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV…
- Trial name
- NCT01828099
- Testing
- Ceritinib, Pemetrexed, Cisplatin
- Where
- 167 sites in Argentina, Australia and 27 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.